BioCentury
ARTICLE | Clinical News

Zavicefta: Additional Ph III REPROVE data

April 28, 2017 2:36 PM UTC

Additional data from the double-blind, double-dummy, international Phase III REPROVE trial in 879 patients with HAP, including VAP, showed that 2,000 mg/500 mg IV Zavicefta ceftazidime/avibactam as a 2-hour infusion every 8 hours led to clinical cure rates of 68.8% and 77.4% in the clinically mITT and clinically evaluable populations, respectively, at the TOC visit 21-25 days after randomization vs. 73% and 78.1% for IV meropenem. Data were presented at the European Congress of Clinical Microbiology and Infectious Diseases in Vienna. Previously reported top-line data showed that Zavicefta met the co-primary endpoints of non-inferiority to IV meropenem in improving clinical cure rate at the TOC visit in the clinically mITT and clinically evaluable populations (see BioCentury, Aug. 1, 2016)...

BCIQ Company Profiles

Allergan plc

Pfizer Inc.

BCIQ Target Profiles

Beta lactamase (LACTB)